Efficacy and safety of combination loratadine/montelukast QD [once daily] vs pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis

Trial Profile

Efficacy and safety of combination loratadine/montelukast QD [once daily] vs pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Loratadine/montelukast; Pseudoephedrine
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 May 2009 Primary endpoint 'Symptom score' has been met.
    • 27 Jun 2008 Schering-Plough and Merck and Co withdraw NDA for loratadine/montelukast combination tablet according to Schering-Plough media release.
    • 05 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top